Home   Log Out   Upgrade   Our Services   My Account   Contact   Help



VivoMedica plc

('VivoMedica' or the 'Company')

Annual General Meeting Statement

VivoMedica plc (AIM:VVM) the pharmaware company, will hold its Annual General Meeting today at 9.00 am at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE. 

At the meeting, Peter Leyland, CEO of VivoMedica will give the following update on the development of the Company's two core technology products, DrugPrint® and PathScoreTM:

DrugPrint® expansion into Human Stem Cells

VivoMedica was delighted to announce its collaboration with Cellartis AB (Goteborg) in June this year, to explore the combination of human Stem Cells (hSC) and the sophisticated analytical capabilities of VivoMedica's DrugPrint® system.

The Company strongly believes that the use of hSC are the way forward in the safety evaluation of medicines, particularly in the successful development of new drugs where the cost of failure is exceptionally high and can prohibit further clinical development of innovative medicines. Our extensive market research indicates that this view is supported by a wide industry consensus, creating a market opportunity that VivoMedica is now well placed to exploit.

VivoMedica's intention is to be a leading player in the safety evaluation of medicines using hSC. Cellartis is the world's largest single source of defined hSC and has developed more than 30 well documented hSC lines. The collaboration is expected to yield discriminatory power needed by the pharmaceutical and biotech industry and increasingly expected by the regulatory authorities. 

DrugPrint® presented to leading scientific conference

In July 2008, VivoMedica presented DrugPrint® data at the 6th International Conference on Substrate-Integrated micro-electrode arrays (MEA) in Reutlingen, Germany. DrugPrint® is the Company's pre-clinical tool to identify drug-induced cardio-toxicity. At this leading conference, which showcases state of the art micro-electrode array technologies, VivoMedica was afforded the opportunity to present the increased discriminatory power of DrugPrint® to an influential academic and scientific peer group audience.  Feedback suggests that the audience considered that the cardiac data presented was both interesting and of high quality. 

Building on this success, VivoMedica will be presenting hSC derived DrugPrint® data at the forthcoming Safety Pharmacology Society conference in Madison WI, USA, to further raise the profile and awareness of DrugPrint® in the pharmaceutical community.

PathScoreTM partners shortlisted 

We are pleased to provide an update on partnering discussions for PathScoreTM, the Company's computerised image analysis system with patented applications that support cancer diagnosis and treatment pathways. The Company now has a shortlist of strategically important potential partners for PathScoreTM and discussions are progressing well. It is envisaged that the partners will support the global commercialisation of this transformational technology. 

Commenting on the update, Professor Sir Christopher Evans, Chairman VivoMedica said: ' I am delighted that VivoMedica's world leading innovations in drug discovery and other aspects of human medical research have recently been so well received by the pharmaceutical industry and several global and medtech companies. Our safety data for drugs using our unique DrugPrint and human stem cells is unparalleled in this industry and I am very excited at the prospects already developing for our world beating PathScore technology. There is plenty more to come from VivoMedica in 2008'.

For further information, please contact:

| Register |  Our Services |  About MoneyAM |  Terms and Conditions |  Privacy Policy |  Investment Warning |  Content Standards |  Corporate Solutions |  Advertise With Us |

2006 MoneyAM©